Allergan announces resolution concluding federal investigation into Warner Chilcott sales and marketing practices
![](/46/pdcnewsitem/03/77/43/allergan.png)
Under the settlement agreements, Warner Chilcott Sales will pay a total of approximately $102 million, plus interest, to the federal government and the states to resolve civil claims.
Allergan’s indirect subsidiary, Warner Chilcott Sales (US) LLC, has reached a resolution with the federal government, as well as 50 states and the District of Columbia, concluding the previously disclosed federal investigation into certain sales and marketing practices involving several Warner Chilcott products during the time period January 2009 through March 2013. In October 2013, Warner Chilcott plc, Warner Chilcott Sales' indirect parent corporation, became a wholly-owned subsidiary of Actavis plc. In March 2015, Actavis plc completed an acquisition of Allergan plc, and thereafter changed its corporate name to Allergan plc.
Under the settlement agreements, Warner Chilcott Sales will pay a total of approximately $102 million, plus interest, to the federal government and the states to resolve civil claims. The settlements will resolve claims regarding a range of alleged sales and marketing activities by Warner Chilcott Sales.
In addition to the civil settlement, Warner Chilcott Sales agreed to plead guilty to a charge of health care fraud in violation of 18 U.S.C. §1347 related to certain of the company's sales and marketing practices prior to its acquisition by Allergan. In connection with the criminal plea, Warner Chilcott Sales will pay a total of approximately $23 million in criminal fines and forfeiture amounts.
The company previously recorded charges of approximately $125 million in connection with the government's investigation.
Following its acquisition of Warner Chilcott Sales, Allergan fully co-operated in the government's investigation and in reaching these civil settlements and plea agreement.
"At Allergan we take seriously our responsibility and commitment to abide by all US and international laws that govern the sales, marketing, education and promotion of our products, and recognize the tremendous impact that this responsibility has on the customers and patients we serve," said Brent Saunders, President and CEO of Allergan. "Our company's culture is deeply rooted in compliance, and we recognize the importance of a strong compliance program. We have focused on developing and implementing a best-in-class set of compliance policies and procedures, and we remain committed to running our business in full compliance with the regulations and high ethical standards we have set for Allergan."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance